Inspire Medical Stock Price, News & Analysis

Inspire Medical Systems (NYSE: INSP) announced its participation at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021. The management team's presentation is scheduled for 10:40 a.m. Eastern Time and will be available via a live webcast. Inspire focuses on innovative, minimally invasive solutions for obstructive sleep apnea, with its Inspire therapy being the first FDA-approved neurostimulation technology for this condition. A replay of the presentation will be accessible for two weeks post-event on Inspire's Investor website.

Inspire Medical Systems (NYSE: INSP) will announce its fourth quarter and full year 2020 financial results on February 23, 2021, following the market's close. A conference call is scheduled for 5:00 p.m. Eastern Time, where management will discuss these results and recent business developments. Inspire specializes in innovative solutions for obstructive sleep apnea, featuring the first FDA-approved neurostimulation technology, Inspire therapy, which offers an effective treatment option for moderate to severe cases.

Inspire Medical Systems has appointed Bryan Phillips as Senior Vice President, General Counsel, and Chief Compliance Officer. With extensive legal experience in the healthcare sector, Phillips aims to support Inspire's growth and therapy adoption. President and CEO Tim Herbert highlighted Inspire's resilience during the pandemic and emphasized the importance of Phillips' expertise in managing the legal aspects of a growing medical device company. Inspire is committed to offering innovative solutions for obstructive sleep apnea.

MINNEAPOLIS, Dec. 22, 2020 - Inspire Medical Systems (NYSE: INSP) announced its participation in the 39th Annual J.P. Morgan Healthcare Conference set for January 13, 2021. The company's presentation is scheduled for 3:40 p.m. Eastern Time and will be accessible via a live webcast. Inspire is recognized for its innovative, minimally invasive solutions for obstructive sleep apnea, including its FDA-approved Inspire therapy. A replay of the presentation will be available for two weeks on Inspire's Investor website.

MINNEAPOLIS, Nov. 18, 2020 – Inspire Medical Systems (NYSE: INSP) announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2, 2020, at 4:30 p.m. Eastern Time. The presentation will be available via a live webcast, with a replay accessible for two weeks afterward on Inspire's Investor website. Inspire focuses on innovative solutions for obstructive sleep apnea, featuring the first FDA-approved neurostimulation technology for treating moderate to severe cases.

Inspire Medical Systems (NYSE: INSP) announced its participation in the 2020 Stifel Virtual Healthcare Conference, scheduled for November 18, 2020, at 11:20 a.m. Eastern Time. The presentation will focus on innovative solutions for obstructive sleep apnea, including their FDA-approved Inspire therapy. A live webcast of the presentation will be available, along with a replay for two weeks afterward on Inspire's Investor website. Inspire is dedicated to developing minimally invasive technologies for treating sleep apnea.

Inspire Medical Systems (NYSE: INSP) announced the integration of its therapy into Germany's hospital reimbursement system effective January 1, 2021. This decision by the Institute for the Hospital Remuneration System (InEK) marks a significant shift from interim NUB reimbursement since 2016 to formal inclusion in the DRG catalog. Inspire's therapy is expected to enhance patient access to treatment for obstructive sleep apnea in Germany, reflecting its acceptance in routine clinical practice.

Inspire Medical Systems, Inc. (NYSE: INSP) reported strong third-quarter results for 2020, with revenues of $35.8 million, marking a 72% year-over-year increase. Gross margin improved to 85.5%, up from 83.4% last year. The company activated 42 new medical centers, exceeding prior guidance, and created seven new sales territories. Inspire raised its full-year revenue guidance to $110 million to $112 million from a prior estimate of $88 million to $92 million, driven by increased patient flow and effective coverage policies.

MINNEAPOLIS, Oct. 27, 2020 – Inspire Medical Systems (NYSE: INSP) announced its management team will present at the Credit Suisse 29th Annual Healthcare Conference on November 10, 2020, at 11:00 a.m. Eastern Time. The presentation will be accessible via a live webcast. Inspire specializes in developing innovative, minimally invasive solutions for obstructive sleep apnea, and its Inspire therapy is the first FDA-approved neurostimulation treatment for this condition. A replay of the presentation will be available for two weeks on Inspire’s investor website.